Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVALT 18: docetaxel versus intercalated erlotinib + docetaxel in relapsed EGFR wild-type, ALK-negative non-squamous NSCLC
NL-OMON45166Phase 3Active, not recruiting
- Sponsor
- NVALT
- Start
- Oct 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of docetaxel, erlotinib in Non-small cell lung cancer (NS-NSCLC), sponsored by NVALT. Started Oct 2016; status: active, not recruiting.
02
Drugs
docetaxelerlotinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on NL-OMON45166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45166.